文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Intranasal spike and nucleoprotein fusion protein-based vaccine provides cross-protection and reduced transmission against SARS-CoV-2 variants.

作者信息

Lakhrif Zineb, Poupée-Beaugé Agathe, Boursin Fanny, Ducournau Céline, Lantier Louis, Moiré Nathalie, Carpentier Rodolphe, Rossignol Christelle, Maquart Marianne, Jospin Fabienne, Merat Laetitia, Caul-Futy Mireille, Yazdanpanah Yazdan, Bouakane Amel, Riou Mickael, Touzé Antoine, Eléouët Jean-François, Richard Charles-Adrien, Helle François, Le Poder Sophie, Klonjkowski Bernard, Meunier Nicolas, Zientara Stéphan, Paul Stéphane, Mévélec Marie-Noëlle, Aubrey Nicolas, Epardaud Mathieu, Dimier-Poisson Isabelle

机构信息

BioMAP, UMR ISP1282 INRAe-Université, Tours, France.

Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France.

出版信息

NPJ Vaccines. 2025 Apr 18;10(1):75. doi: 10.1038/s41541-025-01123-y.

DOI:10.1038/s41541-025-01123-y
PMID:40251181
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12008205/
Abstract

The effectiveness of intramuscular vaccines aimed at preventing severe COVID-19 remains limited due to waning immunity and the emergence of novel variants. Next-generation vaccines are needed for broader protection and blocking virus transmission. Here, we rationally designed an original nasal subunit vaccine composed of a fusion protein (SwFN) made of Wuhan spike and nucleoprotein combined with biocompatible mucosal nanocarriers (Nc). In mouse model, the nasal Nc-SwFN vaccine elicited multivalent serum and mucosal neutralizing antibodies. Robust spike and nucleoprotein cross-reactive immunity against variants was induced with a predominant phenotype of resident memory T cells in the lungs. Moreover, Nc-SwFN led to protective responses against Wuhan and Delta infection in relevant models with an absence of morbidity, mortality, and virus dissemination in the lungs and brain. Finally, Nc-SwFN drastically reduced host-to-host transmission. These promising results underscore the advantages of the nasal Nc-SwFN approach as a broad-spectrum vaccine candidate against current and emerging SARS-CoV-2 variants.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/1afdca0982e6/41541_2025_1123_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/fb4e5050fbc4/41541_2025_1123_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/e4655616fda3/41541_2025_1123_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/2e543b1a4917/41541_2025_1123_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/b9510931dddf/41541_2025_1123_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/aa6dd85982a1/41541_2025_1123_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/6d288f9b42a4/41541_2025_1123_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/4d753cdc346e/41541_2025_1123_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/1afdca0982e6/41541_2025_1123_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/fb4e5050fbc4/41541_2025_1123_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/e4655616fda3/41541_2025_1123_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/2e543b1a4917/41541_2025_1123_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/b9510931dddf/41541_2025_1123_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/aa6dd85982a1/41541_2025_1123_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/6d288f9b42a4/41541_2025_1123_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/4d753cdc346e/41541_2025_1123_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/295a/12008205/1afdca0982e6/41541_2025_1123_Fig8_HTML.jpg

相似文献

[1]
Intranasal spike and nucleoprotein fusion protein-based vaccine provides cross-protection and reduced transmission against SARS-CoV-2 variants.

NPJ Vaccines. 2025-4-18

[2]
MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.

Front Immunol. 2024

[3]
A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.

mBio. 2022-8-30

[4]
SARS-CoV-2 spike-FLIPr fusion protein plus lipidated FLIPr protects against various SARS-CoV-2 variants in hamsters.

J Virol. 2024-2-20

[5]
An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.

Front Immunol. 2021

[6]
Mucosal SARS-CoV-2 S1 adenovirus-based vaccine elicits robust systemic and mucosal immunity and protects against disease in animals.

mBio. 2025-1-8

[7]
Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.

Vaccine. 2023-11-22

[8]
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.

Mol Ther. 2022-9-7

[9]
Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.

J Virol. 2024-9-17

[10]
Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.

Front Immunol. 2022

本文引用的文献

[1]
Mucosal SARS-CoV-2 vaccination of rodents elicits superior systemic T central memory function and cross-neutralising antibodies against variants of concern.

EBioMedicine. 2024-1

[2]
Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes.

Viruses. 2023-2-3

[3]
SARS-CoV-2 variant biology: immune escape, transmission and fitness.

Nat Rev Microbiol. 2023-3

[4]
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models.

Sci Transl Med. 2022-9-14

[5]
Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.

Proc Natl Acad Sci U S A. 2022-5-17

[6]
The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan.

mBio. 2022-6-28

[7]
COVID-19 intranasal vaccines: current progress, advantages, prospects, and challenges.

Hum Vaccin Immunother. 2022-11-30

[8]
Intranasal COVID-19 vaccines: From bench to bed.

EBioMedicine. 2022-2

[9]
Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice.

J Virol. 2022-3-23

[10]
An Intranasal OMV-Based Vaccine Induces High Mucosal and Systemic Protecting Immunity Against a SARS-CoV-2 Infection.

Front Immunol. 2021

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索